EHT 1610
CAS No. : 1425945-60-3
| Size | Price | Stock |
|---|---|---|
| 5mg | $450 | In-stock |
| 10mg | $675 | In-stock |
| 25mg | $1215 | In-stock |
| 50mg | $1825 | In-stock |
| 100mg | $2738 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-111380 |
| M.Wt: | 383.40 |
| Formula: | C18H14FN5O2S |
| Purity: | >98 % |
| Solubility: | DMSO : 5 mg/mL (ultrasonic) |
EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis[1]-[4].
IC50 & Target: IC50: 0.36 nM (DYRK1A), 0.59 nM (DYRK1B)[1]
In Vitro: EHT 1610 induces apoptosis of primary ALL cells that were resistant to cytarabine[2].
EHT 1610 dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric[2].
EHT 1610 (; 72 h) inhibits DYRK1A, results loss of DYRK1A-mediated FOXO1 and STAT3 signaling, leading to preferential cell death in leukemic B cells[3].
EHT 1610 (2.5-10 μM; 4-5 h) inhibits phosphorylation of FOXO1, STAT3 and cyclin D3, thus regulates late cell-cycle progression, mitochondrial ROS and DNA damage, respectively[3].
In Vivo: EHT 1610 (20 mg/kg/d; i.p.; twice a day; 3 weeks) shows antileukemia activity against in leukemic aggressive model in mice[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- EHT 1610
- Cat. No.:
- HY-111380
- Quantity:
Your information is safe with us.